Protagenic Therapeutics, Inc. has made progress in its clinical trial for a new brain peptide compound called PT00114.

The Phase 1b/2a AMARONE clinical trial's 12-week results indicate that Restoret, developed by Eyebiotech Limited, is well-tolerated in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD).

Medicenna Therapeutics has initiated a Phase 1/2 clinical trial, known as the ABILITY-1 study, to assess the safety and efficacy of MDNA11, a modified version of interleukin-2 (IL-2).

A recent clinical study by Kiromic BioPharma, Inc. has shown positive results in the treatment of stage 4 metastatic non-small cell lung cancer (NSCLC) with their drug candidate, Deltacel™.

Carrick Therapeutics has initiated a Phase 1b/2 clinical trial to test the efficacy and safety of a combined treatment of samuraciclib (CT7001) and vepdegestrant (ARV-471) in patients.

AIM ImmunoTech Inc. has initiated a Phase 1b/2 clinical trial at Erasmus Medical Center for patients with advanced pancreatic cancer.

The European Medicines Agency (EMA) has approved the filings by Henlius and Organon for their biosimilar candidate HLX14 to Prolia® and Xgeva® (denosumab).

Kymera Therapeutics Unveils Novel Preclinical Findings for KT-621, an Oral STAT6 Degrader, at ATS Conference.

Scholar Rock begins Phase 2 EMBRAZE trial for Apitegromab and reveals new preclinical results for SRK-439 in treating obesity.

Zai Lab Limited announced the dosing of the first participant in a global Phase 2 trial of its anti-IL-17 treatment, ZL-1102, for chronic plaque psoriasis.

To facilitate systematic and intuitive searching and research of ASCO conference clinical results, the synapse database has launched a new dedicated section for the 2024 ASCO conference clinical results.

Dyne Therapeutics Reveals Latest Clinical Results from ACHIEVE Study of DYNE-101 in DM1 and DELIVER Study of DYNE-251 in DMD Highlighting Significant Effects on Key Disease Indicators and Improvements in Several Functional Outcomes.